Research programme: exosomes based neurological disorder therapeutics - Xosomix
Latest Information Update: 07 Oct 2022
At a glance
- Originator Xosomix
- Developer National Institutes of Health (USA); Xosomix
- Class Exosome therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alzheimer's disease; Rett syndrome